A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2018
At a glance
- Drugs BIIB-078 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 15 Nov 2018 Number of treatment arm has been changed from 5 to 7, and Planned number of patients also increased.
- 15 Nov 2018 Planned number of patients changed from 59 to 80.
- 15 Nov 2018 Planned End Date changed from 29 Nov 2020 to 11 Jul 2022.